Autoimmune polyendocrine syndromes associated with autoimmune rheumatic diseases.
Katarzyna JankowskaPiotr DudekMałgorzata StasiekKatarzyna SuchtaPublished in: Reumatologia (2023)
Autoimmune polyendocrine syndromes (APSs), also called autoimmune polyglandular syndromes, are a group of autoimmune diseases characterized by the co-occurrence of dysfunctions of several (at least two) endocrine glands. They develop under the influence of environmental factors in genetically predisposed people. Autoimmune polyendocrine syndromes may accompany autoimmune rheumatic diseases and worsen their course - APS-2 and APS-3 are the most common. The APS-2 includes the coexistence of, e.g. Hashimoto's disease, celiac disease and rheumatoid arthritis (RA). In APS-3, rheumatic diseases such as RA, systemic lupus erythematosus, and Sjögren's syndrome may coexist with Hashimoto's disease, type 1 diabetes and hypogonadism or other endocrinopathies. Undiagnosed endocrine diseases may be the reason for the intensification of metabolic disorders observed in the course of rheumatic diseases, cause the ineffectiveness of rheumatological treatment and also increase the frequency of bone fractures due to osteoporosis, cardiovascular complications and even miscarriages when coexistent, e.g. Hashimoto's disease with hypothyroiditis, which increases the risk of pregnancy loss. It is important to be able to conduct an extensive interview, paying attention to the symptoms of possible endocrinopathy as well as the features of other autoimmune disorders in the physical examination (e.g. vitiligo or darkening of the skin in Addison's disease). Depending on the history and physical examination, screening for various APSs is advised.
Keyphrases
- rheumatoid arthritis
- multiple sclerosis
- type diabetes
- systemic lupus erythematosus
- disease activity
- drug induced
- mental health
- celiac disease
- physical activity
- insulin resistance
- bone mineral density
- cardiovascular disease
- ankylosing spondylitis
- skeletal muscle
- risk factors
- replacement therapy
- soft tissue
- interstitial lung disease